- Home
- ERNA vs TNON Comparison
ERNA vs TNON Comparison
Compare ERNA & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | TNON |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | TNON |
|---|---|---|
| Price | $0.29 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.10 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | $19.56 |
| Revenue Next Year | N/A | $71.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 755.88 | N/A |
| 52 Week Low | $0.15 | $0.64 |
| 52 Week High | $3.00 | $5.85 |
Technical Indicators
Market Signals| Indicator | ERNA | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 44.18 |
| Support Level | $0.27 | $0.64 |
| Resistance Level | $0.40 | $1.18 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 18.69 | 55.05 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.